SEARCH · Search PubMed
Results for “SULFINPYRAZONE”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Allopurinol in the treatment of gout.
Explore the source record for details and available documents.
The anturane reinfarction trial.
Explore the source record for details and available documents.
Cardiac death prevention in post-myocardial infarction patients: a review.
Explore the source record for details and available documents.
[Symposium "The after care of myocardial infarct with the aggregation inhibitor ANTURAN 200 mg for the reduction of the mortality risk"].
Explore the source record for details and available documents.
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Explore the source record for details and available documents.
[Role of medical treatment in the rehabilitation of the coronary patient].
Explore the source record for details and available documents.
[Correction of thrombophilia].
Explore the source record for details and available documents.
[Prevention of recurrent myocardial infarct].
Explore the source record for details and available documents.
[Prevention of sudden cardiac death].
Explore the source record for details and available documents.
Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study.
In a multicentre double-blind randomised study comparing the effects of sulphinpyrazone 400 mg twice daily with those of placebo in patients after myocardial infarction 727 patients (365 on sulphinpyrazone, 362 on placebo) were enrolled and followed up for 12-48 months (mean 19.2). Treatment began 15-25 days after infarction. There were 49 reinfarctions (9 fatal, 40 nonfatal)-34 occurred in the placebo group and 15 in the sulphinpyrazone group, a reduction of 56%. In addition, a significant reduction of thromboembolic events was noted. It is concluded that sulphinpyrazone is effective in the prevention of reinfarction in patients surviving a recent myocardial infarction.
[Inhibitors of thrombocytic function for prophylaxis of coronary heart disease (author's transl)].
Explore the source record for details and available documents.
[Infarction prophylaxis--prevention of the sudden heart death? An alternative].
Explore the source record for details and available documents.
[Prevention of ischemic cardiopathy, with special reference to secondary prevention in the post-infarct period].
Explore the source record for details and available documents.
[Prevention of myocardial infarction by chemotherapy].
Explore the source record for details and available documents.
Antiplatelet agents: rationale and results.
Explore the source record for details and available documents.
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Explore the source record for details and available documents.